Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer

PURPOSE: Oral mucositis (OM) remains a common, debilitating toxicity of radiation therapy (RT) for head and neck cancer. The goal of this phase IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy and safety of GC4419, a superoxide dismutase mimetic, with placebo to r...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Carryn M., Lee, Christopher M., Saunders, Deborah P., Curtis, Amarinthia, Dunlap, Neal, Nangia, Chaitali, Lee, Arielle S., Gordon, Sharon M., Kovoor, Philip, Arevalo-Araujo, Roberto, Bar-Ad, Voichita, Peddada, Abhinand, Colvett, Kyle, Miller, Douglas, Jain, Anshu K., Wheeler, James, Blakaj, Dukagjin, Bonomi, Marcelo, Agarwala, Sanjiv S., Garg, Madhur, Worden, Francis, Holmlund, Jon, Brill, Jeffrey M., Downs, Matt, Sonis, Stephen T., Katz, Sanford, Buatti, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881100/
https://www.ncbi.nlm.nih.gov/pubmed/31618127
http://dx.doi.org/10.1200/JCO.19.01507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881100/
https://www.ncbi.nlm.nih.gov/pubmed/31618127
http://dx.doi.org/10.1200/JCO.19.01507

Ejemplares similares